SMFM Notice: Bicillin® L-A Recall

Posted: July 18, 2025
Last Updated: July 28, 2025

This guidance was developed by the Society for Maternal-Fetal Medicine (SMFM) Committee on Infectious Diseases and Emerging Threats with the assistance of Naima Joseph, MD, MPH and Brenna Hughes, MD, MSc.

This document has been updated as follows:

- Includes SMFM support of the use of Extencilline and Lentocilin© for treatment of patients with syphilis in pregnancy when Bicillin® L-A is unavailable.

Background

On July 10, 2025, King Pharmaceuticals LLC., a subsidy of Pfizer, issued a notice informing customers about a new voluntary **recall** of selected lots of **Bicillin® L-A (Penicillin G Benzathine Injectable Suspension)** distributed from December 11, 2023 through June 24, 2025**.** Pfizer is initiating this recall due to particulates identified during visual inspection. The lots included are listed below.

Carton NDC	Syringe NDC	Lot Number	Expiration Date YYMMDD	Strength	Configuration/ Count
60793-701-10	60793-701-02	GL2954	270131	1,200,000 units/ 2 mL	10 (2 mL) syringes per carton, 24 cartons per shipping case
		HP6222	270131		
		HP6228	271031		
		HP6232	270930		
		HR9967	270531		
		HJ3235	260930		
		LT5190	270930		
60793-702-10	60793-702-04	GT2598	260930	2,400,000 units/ 4 mL	10 (4 mL) syringes per carton, 24 cartons per shipping case
		GT2599	260930		
		HR9969	270430		
		HK2909	270228		
		HR9984	270831		

Society for Maternal•Fetal Medicine

Extencilline (benzathine Benzylpenicillin) and Lentocilin© (Benzathine Benzylpenicillin Tetrahydrate) were approved by the Food & Drug Administration (FDA) for temporary importation due to prior shortages and remain available for those who are affected by this recall and have challenges procuring sufficient Bicillin® L-A to meet their needs.

SMFM supports the use of Extencilline and Lentocilin© for treatment of patients with syphilis in pregnancy when Bicillin® L-A is unavailable.